<DOC>
	<DOC>NCT01485887</DOC>
	<brief_summary>This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study. This study consists of 10 month treatment phase and 1-3 week tapering phase. The 2 follow-up visits will be evaluated after 2 weeks and 4 weeks of last study medication dosing.</brief_summary>
	<brief_title>Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Outpatients who have completed 8 weeks doubleblind study (B2411263), without major protocol violations or tolerability concerns in the opinion of the investigator. Clinically important abnormalities on baseline (Week 8 of the doubleblind study) physical examination, or any unresolved clinically significant abnormalities on electrocardiogram (ECG), laboratory test results, or vital signs recorded before Week 8 in the previous doubleblind study. Significant risk of suicide based on clinical judgment. Use of prohibited treatments</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Venlafaxine ER</keyword>
	<keyword>long-term extension</keyword>
	<keyword>Japan</keyword>
</DOC>